
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his final trade.
On Aug. 20, AstraZeneca released complete results from the BaxHTN Phase 3 trial evaluating baxdrostat. The Cambridge, U.K.-based company released the topline data in July.